Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...
Some of our patients often tell us they need to experience some undesirable truth first-hand to believe it. Implied is the ...
Ketamine is an old anesthesia drug with psychedelic qualities, and it has been getting a lot of attention for its ability to ...
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...
In the second episode of The Deep End, listeners hear what it’s like to live with severe depression and the backstory of an experimental treatment.
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...
The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is ...